The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.

A hydrotropic composition including at least one surface active cationic component, which is selected from a group of cholinium, guadinium or tetramethylguadinium, preferably cholinium, and a straight or branched carboxylate anion having at least six carbon atoms and its uses, for treating of oil sands or the like, for treating tailings from separation of bitumen, asphaltenes or the like.

This invention relates to using a guanidinium-based ionic liquid as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the absorbent is a guanidinium-based ionic liquid. A preferred refrigerant is water. This invention also provides a method for synthesizing N,N,N,N,N,N-hexamethylguanidinium acetate.

This invention relates to using a guanidinium-based ionic liquid as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the absorbent is a guanidinium-based ionic liquid. A preferred refrigerant is water. This invention also provides a method for synthesizing N,N,N,N,N,N-hexamethylguanidinium acetate.

A hydrogen barrier agent capable of imparting hydrogen barrier performance to various materials; a hydrogen barrier film forming composition including the hydrogen barrier agent; a hydrogen barrier film including the hydrogen barrier agent; a method for producing a hydrogen barrier film, which uses the composition; and an electronic element provided with the hydrogen barrier film. A salt compound having a specific structure including an imidazolyl group is used as the hydrogen barrier agent. The composition is prepared by blending the hydrogen barrier agent into the base material component. The hydrogen barrier film is formed using the hydrogen barrier film forming composition.

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

The use of a catalyst of the formula (I) for the crosslinking of a curable composition. The catalyst of the formula (I) contains at least one aliphatic guanidine group. It is substantially odorless and nonvolatile at room temperature and accelerates the crosslinking of curable compositions very efficiently, without impairing the storage stability thereof. It is particularly suitable for compositions based on polymers containing silane groups, where it has very good compatibility, as a result of which such compositions do not have a tendency to separation or migration or evaporation of the catalyst.

The use of a catalyst of the formula (I) for the crosslinking of a curable composition. The catalyst of the formula (I) contains at least one aliphatic guanidine group. It is substantially odorless and nonvolatile at room temperature and accelerates the crosslinking of curable compositions very efficiently, without impairing the storage stability thereof. It is particularly suitable for compositions based on polymers containing silane groups, where it has very good compatibility, as a result of which such compositions do not have a tendency to separation or migration or evaporation of the catalyst.